Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).
Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Hong Jae Chon, Masatoshi Kudo, Martin Schönlein, Johann von Felden, Brooke Wietharn, Samuel Phen, Bernhard Scheiner, Lorenz Balcar, Yi‐Hsiang Huang, Tiziana Pressiani, Gianluca Masi, Abdul Rafeh Naqash, Dominik Bettinger, Arndt Vogel, Peter R. Galle, Vince Gaillard, Celina Ang (2023). Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).. , 41(4_suppl), DOI: https://doi.org/10.1200/jco.2023.41.4_suppl.504.
